A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer

Immune channel inhibitor–induced myocarditis is rare, and its management is challenging. Recently, guidelines were established for all ICIs, yet they do not take into account individual drug toxicities or screening protocols for prevention. We present a rare case of rapidly progressive pembrolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Max, Mustafa, Saim, Elkherpitawy, Islam, Meleka, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Focus Issue on Heart Failure
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311714/
https://www.ncbi.nlm.nih.gov/pubmed/34317255
http://dx.doi.org/10.1016/j.jaccas.2019.12.045
Descripción
Sumario:Immune channel inhibitor–induced myocarditis is rare, and its management is challenging. Recently, guidelines were established for all ICIs, yet they do not take into account individual drug toxicities or screening protocols for prevention. We present a rare case of rapidly progressive pembrolizumab-induced fatal myocarditis in an initially asymptomatic patient. (Level of Difficulty: Beginner.)

Ejemplares similares